Summary for Clinicians: Clinical Practice Guideline for the Treatment of Systemic Sclerosis–associated Interstitial Lung Disease
An evidence-based guideline for the treatment of patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD) was created in 2023 by a panel of multidisciplinary experts. 
Category
  • General Interest
  • Pulmonary
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $25.00
Lung Disease and Social Justice: Chronic Obstructive Pulmonary Disease as a Manifestation of Structural Violence
Lung health, the development of lung disease, and how well a person with lung disease is able to live all depend on a wide range of societal factors. These systemic factors that adversely affect people and cause injustice can be thought of as “structural violence.”
Category
  • General Interest
  • Pulmonary
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $25.00
The Puzzle of Marijuana Use and Forced Vital Capacity
In study after study, marijuana use has been found to be associated with increased forced vital capacity (FVC). This is puzzling, because marijuana is commonly consumed by inhalation of its smoke, and smoke exposure of any kind is not generally considered a cause of increased FVC.
Category
  • General Interest
  • Pulmonary
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $25.00
Access to Treatment for Chronic Obstructive Pulmonary Disease in the Americas: A Call for Action
Chronic obstructive pulmonary disease (COPD) is a major public health problem in the Americas (a region of the world comprising North, Central, and South America), although there is substantial variation in disease prevalence, morbidity, and mortality between and within nations.
Category
  • General Interest
  • Pulmonary
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $25.00
The Management of Mild Pulmonary Hypertension in Clinical Practice
The definition of pulmonary hypertension (PH) has been revised recently, with the mean pulmonary artery pressure (mPAP) threshold (assessed by right heart catheterization) reduced from ≥25mm Hg to >20mm Hg.
Category
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $0.00
Detecting Alpha-1 Antitrypsin Deficiency: Current State, Impediments, Opportunities, and Future Directions
Alpha-1 antitrypsin deficiency (AATD) is an underrecognized condition with only a small minority of affected individuals diagnosed, long delays between initial symptoms and diagnosis, and evidence that affected individuals may see many physicians with suggestive symptoms before an initial diagnos
Category
  • General Interest
  • Pulmonary
Format
  • Journal
Credits
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Participation
Cost $25.00

Pages